Valeant Comments On Issued Philidor Criminal Charges
LAVAL, Quebec, Nov. 17, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today learned that a criminal complaint was filed in relation to Philidor. Gary Tanner and Andrew Davenport were charged in the matter. The company, former CEO, former CFO, and current executives have not been charged at this time. Gary Tanner ceased to be a Valeant employee on September 13, 2015, and Andrew Davenport has never been an employee of the Company. The counts issued today include allegations that the charged parties engaged in actions to defraud Valeant as a company. Valeant continues to cooperate with all relevant authorities in this matter.
About Valeant Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.
Contact Information:
Elif McDonald[email protected]514-856-3855 877-281-6642 (toll free)
Media:Renée SotoorChris Kittredge/Jared LevySard Verbinnen & Co.212-687-8080
Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-comments-on-issued-philidor-criminal-charges-300365174.html
SOURCE Valeant Pharmaceuticals International, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JBM Exclusively Lists Integra Palms in Riverview, FL
- Blue Lizard® Brand Sunscreen Named First Official Sunscreen Partner of the Manning Passing Academy
- The World Cup Is Bringing North America Together. MADD Canada and MADD Are Uniting to Keep Fans Safe
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
DavenportSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share